PATIENT INFORMATION
The clinical study phase IIb with LT-02 in patients who suffer from active ulcerative colitis is under evaluation.
This phase IIb study is performed with support from Dr. Falk Pharma, Freiburg, Germany.
Patients who have participated in the study can contact their study center for further information.
LIPID THERAPEUTICS GmbH
Alte Glockengiesserei 9
69115 Heidelberg
Germany
| Tel.: Fax: Email: |
+49 (0) 6221 33 50 58-0 (9am – 5pm) +49 (0) 6221 33 50 58-9 info@lipid-therapeutics.com |